Dr Lal PathLabs Scales Genomics with Illumina's NovaSeq X

Dr Lal PathLabs has enhanced its genomic capabilities by acquiring Illumina's NovaSeq X Series to the dedicated genomics division Genevolve. This additional technology expands the lab's ability to provide rapid and reliable genomic information for research and diagnostics.

The NovaSeq X system utilizes Illumina's next-gen XLEAP-SBS chemistry which increases throughput and accuracy while improving sustainability. The NovaSeq X Plus is capable of sequenced over 20,000 Whole genomes per year, more than double prior models of NovaSeq X and provides flexibility and rapidity for the next-generation sequencing (NGS).

“With the addition of Illumina’s NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence. This investment allows us to broaden our capabilities and contribute meaningfully to India’s evolving genomics landscape,” said Shankha Banerjee, CEO, Dr. Lal PathLabs Limited.

Founded in 2019, Genevolve has quickly advanced as a DNA-based centre of excellence.  The integration of Illumina's newest platform builds on their expertise in NGS, as well as, their ability to provide AI-based genomic insight with improved ability and sensitivity.

Also Read: The Future of Genomic Sequencing: Trends That Will Define the Next Decade

“At Genevolve, our mission has always been to push the boundaries of genomic innovation. Bringing the NovaSeq X Series into our portfolio is a testament to that commitment, combining the power of next-generation sequencing and AI to enable faster, more precise and meaningful insights for better outcomes,” said Dr. Vandana Lal, executive director, Dr. Lal PathLabs Limited.

According to a company announcement, Dr Lal PathLabs and Illumina, will work with India's medical research and science communities to raise awareness and build capacity for genomics-based decision-making within the health care and research ecosystems.